In this review, the authors discuss contemporary methodologies employed to investigate possible associations between vaccination and adverse neurological outcomes and why determining causality can be challenging.

This cohort study evaluates the COVID-19-related case fatality rate (CFR) of patients with pre-existing neurological diseases.

In this article the authors performed a systematic literature review on neuropathological studies in COVID-19, including 438 patients from 45 articles published by April 22, 2021.

The objective of this study was to investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD. Blood samples were collected in patients diagnosed with COVID-19.

This critical review highlights the injury pathways possible through SARS-CoV-2 infection that have the potential to increase and contribute to cognitive impairment and dementia.

In this article the authors searched 3 databases (PubMed, MEDLINE, and CINAHL) with search terms COVID-19, novel coronavirus, stroke, and cerebrovascular accident.

This review aims to provide a clinical practice-oriented approach to SARS-CoV-2 vaccination in MS in the era of the COVID-19 pandemic.

Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, the authors systematically included worldwide reported cases on this association.

In this study the authors analyzed COVID-19 patients of 127 centers, diagnosed between 01/2020 and 02/2021, and registered at the European multinational LEOSS registry ‘Lean European Open Survey on SARS-Infected Patients’.

In this article the authors detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19.

In this article, the authors provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern.

The authors of this article hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity.

The authors analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020.

The objective of this prospective cohort study was to determine associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with COVID-19 among nursing home residents, nursing home staff, and healthcare workers.

The objective of this test negative design study was to estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).